Cancer drug combo trial ends early – little known
NCT ID NCT04986852
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tested a combination of two drugs, olinvacimab and pembrolizumab, in 19 women with metastatic triple-negative breast cancer. The goal was to see if the combination could shrink tumors. However, the study was terminated early, so we have limited information on how well it worked or its safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- olinvacimab and pembrolizumab
- What this could lead to
- If it worked, this combination could have offered a new treatment option for metastatic triple-negative breast cancer.
- What could go wrong
- The trial was terminated early with only 19 participants, so we have very little data. It is unclear if the combination is effective or safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hollywood Private Hospital
Nedlands, Western Australia, 6009, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
- New drug targets Hard-to-Treat cancers in japanese patients
- Could a simple capsule beat chemo fatigue? new trial aims to find out
- Experimental cell therapy targets multiple cancers in early trial
- Scientists hunt for clues to better treat aggressive breast cancer
- New pill takes on tough breast cancer in first human trial